USER: User-Sensitive Expert Recommendations for Knowledge-Dense Environments

2006 ◽  
pp. 77-95 ◽  
Author(s):  
Colin DeLong ◽  
Prasanna Desikan ◽  
Jaideep Srivastava
Keyword(s):  
Expert Recommendations

scholarly journals Considerations for and Mechanisms of Adjunct Therapy in COPD

2021 ◽  
Vol 10 (6) ◽  
pp. 1225
Author(s):  
Rachana Mandru ◽  
Christine Y. Zhou ◽  
Rachel Pauley ◽  
Robert M. Burkes
Keyword(s):  
Vitamin D ◽  
Adverse Events ◽  
Hypertonic Saline ◽  
Clinical Data ◽  
Therapeutic Approach ◽  
Vitamin D Supplementation ◽  
Review Article ◽  
Macrolide Antibiotics ◽  
Oral Corticosteroids ◽  
Expert Recommendations

Inhaled bronchodilators and corticosteroids, when indicated, form the backbone of COPD therapy. However, over the last decade there has been an emergence of adjunct therapies in oral or inhaled form that are now part of the therapeutic approach to COPD. While these therapies have shown to be beneficial when used in the appropriate instances, there are particular considerations that need to be minded when using these therapies. This review article discussed the mechanism of roflumilast, macrolide antibiotics, other chronic antibiotic regimens, vitamin D supplementation, oral corticosteroids, n-acetylcysteine, and nebulized hypertonic saline, the clinical data behind each of these therapies, adverse events associated with therapy, and the expert recommendations for their utilization. Our goal is to provide a brief but informative and clinically useful review of commonly encountered therapies used in advanced COPD.

scholarly journals Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Virginia Ronco ◽  
Myriam Dilecce ◽  
Elena Lanati ◽  
Pier Luigi Canonico ◽  
Claudio Jommi
Keyword(s):  
Selection Process ◽  
Grey Literature ◽  
Primary Objective ◽  
Medicinal Products ◽  
Health Authorities ◽  
Advanced Therapy ◽  
Additional Funding ◽  
Managed Entry Agreements ◽  
R Process ◽  
Expert Recommendations

Abstract Background Advanced therapy medicinal products (ATMPs) represent an important cornerstone for innovation in healthcare. However, uncertainty on the value, the high average cost per patient and their one-shot nature has raised a debate on their assessment and appraisal process for pricing and reimbursement (P&R) purposes. This debate led experts providing for recommendations on this topic. Our primary objective is to investigate the ATMPs P&R process in the main five European countries and to understand if this process is consistent with published P&R expert recommendations. We also investigated the current ATMP pipelines to understand if future ATMPs will create challenges for their P&R process. Methods P&R framework for ATMPs in the European Major five (EU5) countries was investigated through a literature search on PubMed, institutional websites of National Health Authorities and grey literature. The ATMPs pipeline database was populated from a clinical trial database (clinicaltrials.gov), relying on inclusion and exclusion criteria retrieved from the literature. Results Reimbursement status of ATMPs is different across the EU5 countries, with the exception of CAR-Ts which are reimbursed in all countries. Standard P&R process in place for other medicinal products is extended to ATMPs, with the exception of some cases in Germany. List prices, where available, are high and, tend to be aligned across countries. Outcome-based Managed Entry Agreements (MEAs) have been extensively used for ATMPs. Extra-funds for hospitals managing ATMPs were provided only in Germany and, as additional fund per episode, in France. The accreditation process of hospitals for ATMPs management was in most countries managed by the national authorities. As far as ATMPs pipeline is concerned, ATMPs in development are mostly targeting non-rare diseases. Conclusions Expert recommendations for ATMPs P&R were partially applied: the role of outcome-based MEAs has increased and the selection process of the centres authorized to use these treatments has been enhanced; additional funding for ATMPs management to accredited centres has not been completely considered and annuity payment and broader perspective in cost considerations are far from being put in place. These recommendations should be considered for future P&R negotiations to pursue rational resource allocation and deal with budget constraints.

scholarly journals Fabry disease and COVID-19: International expert recommendations for management based on real-world experience

2021 ◽  
Vol 132 (2) ◽  
pp. S62
Author(s):  
Dawn A. Laney ◽  
Dominique P. Germain ◽  
João Paulo Oliveira ◽  
Alessandro P. Burlina ◽  
Gustavo H. Cabrera ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Real World ◽  
International Expert ◽  
Expert Recommendations

A Bayesian-Network-based Approach to Risk Analysis in Runway Excursions

2019 ◽  
Vol 72 (5) ◽  
pp. 1121-1139 ◽  
Author(s):  
Fernando Calle-Alonso ◽  
Carlos J. Pérez ◽  
Eduardo S. Ayra
Keyword(s):  
Risk Analysis ◽  
Bayesian Network ◽  
Exploratory Analysis ◽  
Hypothesis Tests ◽  
Aircraft Accidents ◽  
Risk Scenarios ◽  
Key Variables ◽  
Expert Recommendations

Aircraft accidents are extremely rare in the aviation sector. However, their consequences can be very dramatic. One of the most important problems is runway excursions, when an aircraft exceeds the end (overrun) or the side (veer-off) of the runway. After performing exploratory analysis and hypothesis tests, a Bayesian-network-based approach was considered to provide information from risk scenarios involving landing procedures. The method was applied to a real database containing key variables related to landing operations on three runways. The objective was to analyse the effects over runway overrun excursions of failing to fulfil expert recommendations upon landing. For this purpose, the most influential variables were analysed statistically, and several scenarios were built, leading to a runway ranking based on the risk assessed.

Combination Treatments for Schizophrenia

CNS Spectrums ◽  
2004 ◽  
Vol 9 (S9) ◽  
pp. 19-23 ◽  
Author(s):  
Alexander L. Miller
Keyword(s):  
Electroconvulsive Therapy ◽  
Cognitive Deficits ◽  
Negative Symptoms ◽  
Current Evidence ◽  
Positive Symptoms ◽  
Combination Therapies ◽  
Safety And Efficacy ◽  
Combination Treatments ◽  
Improved Outcomes ◽  
Expert Recommendations

ABSTRACTCombination treatments, especially combinations of antipsychotics, are used frequently for schizophrenia, despite a paucity of evidence regarding their safety and efficacy. Because the literature basis is weak and expert recommendations are largely lacking, providers should be vigilant in documenting improved outcomes for patients thought to benefit from combination treatments. Target symptoms that have been studied include psychosis, cognitive deficits, and negative symptoms. The strongest evidence is for augmentation of clozapine with another antipsychotic or with electroconvulsive therapy for persistent positive symptoms. Combination treatments for cognitive deficits and negative symptoms are being actively investigated, but current evidence is insufficient to recommend available agents for these components of schizophrenia. It is important that appropriate monotherapies be given adequate trials before resorting to combination therapies.

scholarly journals Expert recommendations on blood purification treatment protocol for patients with severe COVID-19

2020 ◽  
Vol 6 (2) ◽  
pp. 106-114 ◽  
Author(s):  
Xiang-Hong Yang ◽  
Ren-Hua Sun ◽  
Ming-Yan Zhao ◽  
Er-Zhen Chen ◽  
Jiao Liu ◽  
...  
Keyword(s):  
Treatment Protocol ◽  
Blood Purification ◽  
Expert Recommendations
Sign in / Sign up

Export Citation Format

Share Document